Shortly before the turn of the year, the US Food and Drug Administration (FDA) gave Novo Nordisk an important “Christmas present”: the approval of the Wegovy pill.
Outlook 2026: Capacity issues and EMA decision are likely to determine the price of Novo Nordisk shares
